TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science ...

Studies have demonstrated the use of phosphate as a transient protecting group, which enhances the efficiency of enzymatic synthesis and expands the range of nucleic acid analogues that can be ...

TriLink BioTechnologies, a Maravai LifeSciences company and provider of life science reagents and services, has partnered ...

The Nucleic Acids Institute is dedicated to understanding the chemical and biological basis for nucleic acid function, and to developing new and powerful nucleic acids based therapeutic and ...

TriLink is dedicated to advancing nucleic acid therapeutics ... Its growing portfolio of mRNA capping analogs includes the award-winning CleanCap® M6, mRNA raw materials (nucleotides and other ...

Key responsibilities include the synthesis of novel nucleic acid analogues using solution and solid-phase chemistry, characterising compounds and their biological activity through a variety of ...

TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science ...

State Key Laboratory of Oral Diseases, National Center for Stomatology, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan ...

Department of Chemistry, University of California─Irvine, Irvine, California 92697, United States Department of Pharmaceutical Sciences, University of California─Irvine, Irvine, California 92697, ...

TriLink BioTechnologies & Aldveron ink non-exclusive license and supply agreement for CleanCap mRNA capping technology: San Diego, US Thursday, February 6, 2025, 15:00 Hrs [IST] T ...